Zions Bancorporation’s NeoGenomics NEO Stock Holding History

Zions Bancorporation’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-572	Closed	-$5.29K	–	998
2022 Q4	$5.29K	Buy	+572	New	+$5.33K	﹤0.01%	841

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zions Bancorporation's NEO Position: Q1 2023 in Review

Zions Bancorporation sold out of NeoGenomics (NEO) in Q1 2023, closing a stake of 572 shares — an estimated $5.29K sold.

Zions Bancorporation first reported a position in NEO in Q4 2022 and held it in 1 quarter. The position peaked at $5.29K in Q4 2022. 256 funds tracked by Wall St. Rank hold NEO as of Q1 2023.

Zions Bancorporation reported no remaining NeoGenomics position as of Q1 2023 after selling out during the quarter.
Zions Bancorporation sold 572 NeoGenomics shares in Q1 2023, an estimated $5.29K.
Zions Bancorporation first reported a position in NeoGenomics in Q4 2022 and held it in 1 quarter.
Zions Bancorporation's NeoGenomics position peaked at $5.29K in Q4 2022.
256 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2023.

Based on Zions Bancorporation's 13F filing for Q1 2023, filed 10 May 2023.